{
  "id": "oaia2",
  "display_name": "Oral Anti-Inflammatory Asthma Drugs (Leukotriene Receptor Antagonists And Inhibitors Of Lipo-Oxygenase) (SHHS2)",
  "description": "Participant taking ORAL ANTI-INFLAMMATORY ASTHMA DRUGS (LEUKOTRIENE RECEPTOR ANTAGONISTS AND INHIBITORS OF LIPO-OXYGENASE) within two weeks of the SHHS2 visit.  All medications were recorded during the interview, and medication information was later categorized by physician review.",
  "type": "choices",
  "domain": "noyes01",
  "labels": [
    "OAIA2"
  ],
  "commonly_used": true,
  "hybrid": {
    "VARNUM": "296",
    "TABLE": "SHHS2",
    "LABEL": "ORAL ANTI-INFLAMMATORY ASTHMA DRUGS (LEUKOTRIENE RECEPTOR ANTAGONISTS AND INHIBITORS OF LIPO-OXYGENASE)",
    "sensitivity": "0",
    "design_name": "Medication Form (SHHS2)",
    "MEMNAME": "shhs2_1",
    "design_file": "SHHS2 Medications (MD).pdf",
    "PARENT TERM": null
  }
}
